A Clinician's Guide to Progressive Supranuclear Palsy
Description:
This brief, clinically-focused volume is informed by Lawrence I. Golbe’s three decades of research and tertiary clinical care in progressive supranuclear palsy, a complex disorder with rapidly changing diagnostic and therapeutic approaches. It is an ideal source for the general neurologist seeking a refresher and the primary care provider, neurological nurse, or physical, occupational or speech therapist who must address their patients’ specialized needs.
A Clinician’s Guide to Progressive Supranuclear Palsy emphasizes early diagnostic signs, medication options, non-pharmacologic management and palliative care. It offers a quick overview of the complications of PSP most likely to prompt an ER visit; a widening spectrum of PSP variants; and ample description of the genetics, epidemiology, natural history, pathology, molecular biology and neurochemistry of PSP. The PSP Rating Scale used in the book is a convenient tool for clinicians in routine practice and the leading PSP clinical measure world-wide. Golbe provides a practical and useful guidebook to help all clinicians learn and battle this complex disorder.
Best prices to buy, sell, or rent ISBN 9781978803206
Frequently Asked Questions about A Clinician's Guide to Progressive Supranuclear Palsy
The price for the book starts from $136.25 on Amazon and is available from 9 sellers at the moment.
If you’re interested in selling back the A Clinician's Guide to Progressive Supranuclear Palsy book, you can always look up BookScouter for the best deal. BookScouter checks 30+ buyback vendors with a single search and gives you actual information on buyback pricing instantly.
As for the A Clinician's Guide to Progressive Supranuclear Palsy book, the best buyback offer comes from and is $ for the book in good condition.
The A Clinician's Guide to Progressive Supranuclear Palsy book is in very low demand now as the rank for the book is 10,910,702 at the moment. A rank of 1,000,000 means the last copy sold approximately a month ago.
Not enough insights yet.